Amphastar's Q3: Mixed Results, Bright Future
Update: 2025-11-10
Description
Amphastar Pharmaceuticals reported mixed Q3 2025 results, with revenue meeting expectations but sales flat compared to last year. However, non-GAAP profit significantly beat estimates by nearly 13%. Key products BAQSIMI and Primatene MIST drove growth, but operating margins were pressured by product mix shifts, price reductions, and competition. Higher costs and legal provisions also impacted profitability. Amphastar plans to expand its proprietary product pipeline, focusing on oncology and ophthalmology, and aims to quadruple US manufacturing capacity by 2026. Despite potential risks, the company is optimistic about future growth and profitability.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
